# Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct05565807/  
OnCo record `nct05565807` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of STI-6129 in multiple myeloma, run by Zhejiang ACEA Pharmaceutical Co. Ltd., now recruiting.

## Summary

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05565807 by Zhejiang ACEA Pharmaceutical Co. Ltd., with 84 participants planned, started 2023-02-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: STI-6129. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05565807
- Phase: 1/2
- Setting: A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Zhejiang ACEA Pharmaceutical Co. Ltd.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT05565807: https://clinicaltrials.gov/study/NCT05565807

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [STI-6129](https://onco.cc/drugs/sti-6129/)

---
JSON: https://onco.cc/api/v1/entities/nct05565807.json